Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84. https://doi.org/10.1016/j.eururo.2018.08.036.

Article  PubMed  Google Scholar 

Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17:245–61. https://doi.org/10.1038/s41581-020-00359-2.

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Kaelin WG. Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat Med. 2020;26:1519–30. https://doi.org/10.1038/s41591-020-1093-z.

Article  CAS  PubMed  Google Scholar 

Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205. https://doi.org/10.1016/j.ctrv.2007.12.001.

Article  PubMed  Google Scholar 

Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019;16:621–33.

Article  CAS  PubMed  Google Scholar 

Najjar YG, Rini BI. Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol. 2012;4:183–94. https://doi.org/10.1177/1758834012443725.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007;18:x25–31. https://doi.org/10.1093/annonc/mdm411.

Article  PubMed  Google Scholar 

Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022;40:2957–95. https://doi.org/10.1200/JCO.22.00868.

Article  CAS  PubMed  Google Scholar 

Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3. https://doi.org/10.1038/nrdp.2017.9.

Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13:496–511. https://doi.org/10.1038/nrneph.2017.82.

Article  PubMed  Google Scholar 

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370–85. https://doi.org/10.1016/S1470-2045(19)30413-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Méjean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80:417–24. https://doi.org/10.1016/j.eururo.2021.06.009.

Article  CAS  PubMed  Google Scholar 

Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer Vhl. 2014;1:1–11.

Article  PubMed  PubMed Central  Google Scholar 

Dranitsaris G, Schmitz S, Broom RJ. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. J Cancer Res Clin Oncol. 2013;139:1917–26. https://doi.org/10.1007/s00432-013-1510-5.

Article  CAS  PubMed  Google Scholar 

Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. The Oncologist. 2011;16:32–44. https://doi.org/10.1634/theoncologist.2011-S2-32.

Article  PubMed  PubMed Central  Google Scholar 

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26:2107–13. https://doi.org/10.1093/annonc/mdv315.

Article  CAS  PubMed  Google Scholar 

Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, De Simone V. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol. 2014;89:386–93. https://doi.org/10.1016/j.critrevonc.2013.09.002.

Article  PubMed  Google Scholar 

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017;28:1339–45. https://doi.org/10.1093/annonc/mdx075.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamada Y, Ohno Y, Kato Y, Kobayashi R, Hayashi H, Miyahara S, et al. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2019;84:987–92. https://doi.org/10.1007/s00280-019-03935-x.

Article  CAS  PubMed  Google Scholar 

Demlova R, Turjap M, Pes O, Kostolanska K, Jurica J. Therapeutic drug monitoring of sunitinib in gastrointestinal stromal tumors and metastatic renal cell carcinoma in adults—a review. Ther Drug Monit. 2020;42:20–32. https://doi.org/10.1097/FTD.0000000000000663.

Article  PubMed  Google Scholar 

Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17. https://doi.org/10.1186/s12943-018-0801-5.

Neul C, Schaeffeler E, Sparreboom A, Laufer S, Schwab M, Nies AT. Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors. Trends Pharmacol Sci. 2016;37:904–32. https://doi.org/10.1016/j.tips.2016.08.003.

Article  CAS  PubMed  Google Scholar 

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10–9. https://doi.org/10.1093/annonc/mdx703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekino Y, Teishima J, Liang G, Hinata N. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. Int J Urol. 2022. https://doi.org/10.1111/iju.15042.

Tao T, Yang X, Zheng J, Feng D, Qin Q, Shi X, et al. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation. Oncogene. 2017;36:6119–31. https://doi.org/10.1038/onc.2017.199.

Article  CAS  PubMed  Google Scholar 

Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, et al. Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett. 2019;453:107–21. https://doi.org/10.1016/j.canlet.2019.03.043.

Article  CAS  PubMed  Google Scholar 

Wang H, Yang W, Qin Q, Yang X, Yang Y, Liu H, et al. E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Mol Cancer. 2022;21. https://doi.org/10.1186/s12943-022-01622-9.

Dong LH, Wen JK, Miao SB, Jia Z, Hu HJ, Sun RH, et al. Baicalin inhibits PDGF-BB-stimulated vascular smooth muscle cell proliferation through suppressing PDGFRbeta-ERK signaling and increase in p27 accumulation and prevents injury-induced neointimal hyperplasia. Cell Res. 2010;20:1252–62. https://doi.org/10.1038/cr.2010.111.

Article  CAS  PubMed  Google Scholar 

Xue Y, Lim S, Yang Y, Wang Z, Jensen LDE, Hedlund E, et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med. 2012;18:100–10. https://doi.org/10.1038/nm.2575.

Article  CAS  Google Scholar 

Shim M, Song C, Park S, Choi S, Cho YM, Kim C, et al. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2015;141:2213–20. https://doi.org/10.1007/s00432-015-2019-x.

Article  CAS  PubMed  Google Scholar 

Carrato Mena A, Grande Pulido E, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010;21:S3–11. https://doi.org/10.1097/01.cad.0000361534.44052.c5.

Article  CAS  Google Scholar 

Qi Y, Ma Y, Peng Z, Wang L, Li L, Tang Y, et al. Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation. Oncogene. 2020;39:4404–20. https://doi.org/10.1038/s41388-020-1297-1.

Article  CAS  PubMed  Google Scholar 

Lu L, Li Y, Wen H, Feng C. Overexpression of miR-15b promotes resistance to sunitinib in renal cell carcinoma. J Cancer. 2019;10:3389–96. https://doi.org/10.7150/jca.31676.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045–51. https://doi.org/10.1111/j.1365-2133.2009.09290.x.

Article  CAS  PubMed  Google Scholar 

Lankhorst S, Baelde HJ, Kappers MHW, Smedts FMM, Hansen A, Clahsen-van Groningen MC, et al. Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib. Hypertension. 2015;66:543–9. https://doi.org/10.1161/HYPERTENSIONAHA.115.05435.

Article  CAS  PubMed